Bill118th CongressFiled Sep 29, 2023Health
H.R. 5850
To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.
Bill journey · stage 2 of 5
Under committee review
FiledFiled
CommitteeComm.
PassedFloor
Both ChambersBoth
Became LawLaw
What it does
A plain-language summary from the Congressional Research Service isn’t available yet for this bill. CRS summaries are typically posted within a few weeks of introduction.
What just happenedOct 6, 2023
Referred to the Subcommittee on Health.
Who’s behind it
Rep. Mann, Tracey [R-KS-1](R-KS)Sponsor
1 cosponsor1 R
1cosponsors1committees4actions3subjects
- Introduced in HouseSep 29, 2023
- Oct 6, 2023Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Sep 29, 2023IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Sep 29, 2023IntroReferralIntro-H
Introduced in House
- Sep 29, 2023IntroReferral1000
Introduced in House